Stem Cell Treatment Costs in Japan
A public MHLW consent record for one autoimmune-disease plan lists ¥2.2 million including tax per treatment for self-pay autologous adipose-derived MSC administration. It is one plan-specific example, not a Japan-wide price. The real total depends on the exact cells, route, number of sessions, testing, follow-up and travel.[1]
Breaking down what you’re paying for
The treatment fee is only one part of the total.
¥2.2 million is a single data point, not a Japan-wide standard. In the MHLW consent record we’re using here, the amount is ¥2,200,000 including tax per treatment and it’s not covered by public insurance. The same record notes the fee may vary with the patient’s circumstances.[1]
The same record states that costs already incurred after cell collection or processing may remain payable if consent is later withdrawn.[1]
Confirm whether imaging review, laboratory tests, infection screening and condition-specific testing are included.
Autologous cells may require fat, synovium or another tissue collection. Allogeneic products follow a different supply model.
Ask what isolation, expansion, storage, release testing and failed-processing terms are included.
Intravenous infusion, joint injection and surgical implantation have different procedure, monitoring and recovery costs.
Check whether the quote is per infusion, per joint, per treated area or for a full planned course.
Separate repeat tests, rehabilitation, imaging, accommodation, flights, translation and local transport from the cell procedure.
Already got a quote but can’t tell what’s actually included?
Send the treatment name, number of sessions and total price. We can separate the items and flag what still needs clarification.
Inspecting your quote
Make the total clear before you pay.
Cell source, autologous or allogeneic status, product name when applicable, processing method and route.
Dose per administration, number of administrations, interval and whether both sides or multiple areas cost more.
Pre-procedure tests, infection screening, imaging review, follow-up labs and repeat imaging if needed.
What happens if collection is inadequate, culture fails, treatment is postponed or manufactured cells cannot be administered.
Who measures outcome, which score or laboratory marker is used and how long monitoring is included.
Flights, lodging, translation and local transport shown separately rather than hidden inside one package price.
Evidence across conditions
Check what the data say for your diagnosis.
You can’t take results from one disease, one cell source, or one route and paste them onto another. Compare the exact treatment and the endpoint that was actually measured.
The 2025 ADIPOA2 phase 2b randomized trial did not show significant pain and function improvement versus placebo for the studied autologous adipose-derived stromal-cell injection. Japan also has narrowly defined approved regenerative products for specific knee indications; these are not equivalent to every stem-cell injection.[2][3]
In one 91-patient phase II randomized trial, 20% of the UC-MSC group versus 4.55% of placebo reached HbA1c below 7% plus at least 50% insulin reduction at 48 weeks. Beta-cell function did not improve, and the result is not a cure rate.[4]
In Japan’s 206-patient TREASURE trial, excellent outcome at day 90 was 11.5% with MultiStem versus 9.8% with placebo, with no significant difference. It studied one specific allogeneic product given 18 to 36 hours after stroke.[5]
A 2021 Japanese 13-patient case series reported ASIA-grade improvement in 12 of 13 patients after autologous MSC infusion. Without a control group, that figure cannot be used as a personal success rate.[6]
AMCHEPRY received conditional and time-limited approval in 2026 for a defined indication. It is an allogeneic iPS-cell-derived dopaminergic neural progenitor product implanted by stereotactic brain surgery, not an intravenous MSC treatment.[2]
RiHEART received conditional and time-limited approval in 2026 for a defined severe ischemic cardiomyopathy indication. It is an allogeneic iPS-cell-derived cardiomyocyte sheet placed on the heart surface, not a generic infusion.[2]
Measuring what actually matters
Use the outcome that fits your condition.
There is no useful single “stem cell survival rate” across unrelated conditions. Ask what outcome was measured, when it was measured and whether the study had a comparison group.
Pain, WOMAC or KOOS, walking and stair function matter more than a generic response percentage. Symptom improvement does not prove cartilage regeneration.
Use HbA1c, glucose, medication or insulin requirements and C-peptide when relevant. Temporary insulin reduction is not proof of cure.
Functional endpoints are commonly assessed at 90 days and longer follow-up. Rehabilitation and secondary prevention remain important.
Use AIS or ISNCSCI grade, motor and sensory scores, independence measures and rehabilitation progress.
Use the exact study endpoints, procedure-related adverse events and defined longer-term follow-up for that product and population.
Got a diagnosis but the published evidence doesn’t match what you were told?
Send the exact option and your latest reports. We’ll help you figure out which human data are actually comparable—and which aren’t.
What could go wrong—and who shouldn’t proceed
Autologous does not mean risk-free.
Risk depends on the collection method, how cells are processed, the route, dose, disease status, and whether surgery or immunosuppression is involved. Eligibility criteria shift with the exact plan or approved product.
One MHLW public consent record for intravenous adipose-derived MSCs lists risks from fat harvesting and cell administration and notes reports of pulmonary embolism deaths after IV adipose-derived stem cells where the causal relationship was unknown.[1]
Checking Japan’s regulatory system
“Filed in Japan” and “PMDA approved” are not the same.
MHLW provision plan
Japan’s regenerative medicine framework includes public provision-plan records under the Act on the Safety of Regenerative Medicine. A submitted plan and committee review are important checks, but they do not equal marketing approval for a named regenerative medical product.[1][7]
PMDA approved product
PMDA publishes named regenerative medical products with exact indications and approval status. The English list referenced here covers approvals through May 2026. Approval of one product does not validate a different cell source, dose, route or disease claim.[2]
Knee osteoarthritis indication added in 2025 under defined cartilage-defect and prior conservative-treatment criteria.[2]
Approved May 2026 for a defined meniscal-injury setting using autologous synovium-derived MSCs.[2]
Conditional and time-limited 2026 approval for a defined Parkinson’s disease indication and stereotactic implantation.[2]
Conditional and time-limited 2026 approval for severe ischemic cardiomyopathy after inadequate response to standard care.[2]
Have a treatment name or brochure but can’t figure out which Japanese record it belongs to? Send the exact wording—general descriptions won’t help us track it down.
Check What I Have
The support we offer
Japan Cost and Evidence Review.
Think of this as a practical information package—cost, evidence, and public Japanese records pulled together so you can make sense of them before spending a cent on travel or further workup.
Diagnosis, stage, recent tests, current care, previous treatment and the main questions in one concise reference.
Human studies that are reasonably comparable, with differences in cell type, route, disease stage or outcome flagged.
MHLW provision-plan information, PMDA-approved products and registered Japanese clinical studies distinguished when relevant.
Assessment, collection, processing, administration, follow-up, repeat sessions and non-medical travel costs separated.
Points that still need a licensed physician’s answer, including expected outcome, risks, alternatives, rehabilitation and follow-up.
Six things to nail down first
Six answers should be clear before money changes hands.
Source, autologous or allogeneic status, product name when applicable, processing method and route of administration.
Compare disease subtype, severity, cell type, route and outcome, not just the words “stem cells.”
Define the score, laboratory value, imaging measure or functional change before the procedure.
Sessions, both sides or multiple areas, follow-up, repeat testing, failed processing, cancellation and travel should be clear.
Ask for route-specific and procedure-specific risks plus the exact reasons a patient would be excluded or asked to delay.
Medication, rehabilitation, diabetes care, stroke prevention or other established treatment remains defined unless the treating physician changes it.
Dig deeper where it counts
Open the guide that matches your case.
Questions patients often ask
Short answers that change the decision.
Is stem cell treatment in Japan always self-pay?
Does a higher cell count mean a better result?
Can I use one study’s success percentage for my case?
Can cell-based treatment replace rehabilitation or medication?
How do I verify the words “approved in Japan”?
Primary sources and public verification records
- MHLW public consent record: autoimmune-disease plan using autologous adipose-derived MSCs; fee, risk and withdrawal terms.
- PMDA: List of Approved Regenerative Medical Products, April 2015 to May 2026.
- ADIPOA2 phase 2b randomized clinical trial for knee osteoarthritis, 2025.
- Phase II randomized placebo-controlled UC-MSC trial in type 2 diabetes, 2022.
- TREASURE phase 2/3 randomized clinical trial in acute ischemic stroke, 2024.
- Autologous MSC infusion in spinal cord injury: 13-patient case series, 2021.
- MHLW public regenerative medicine provision-plan search.
- Japan Registry of Clinical Trials search.
Information checked 11 August 2026. Fees, regulatory records and evidence can change. Verify current records before a medical or financial decision.
Straightforward decisions
Know what you are comparing before you commit.
Send your diagnosis, recent reports and the quote or treatment description you’re considering. We’ll organize the information, break down the costs, check relevant public records and list the points that still need a licensed physician’s answer.
We provide information and coordination support only. We don’t diagnose, prescribe, offer stem cell treatment, or promise any outcome.